What exactly changed in the SHC analyst rating on Feb 24 2026?

Citigroup maintained a **Buy** on SHC on **February 24, 2026** and raised its price target to **$23** from **$21**. The firm did not lower or raise the Buy conviction, but it did increase the target price.

How should investors use this SHC analyst rating?

Use the SHC analyst rating as one input. The **$23** price target gives an upside reference. Compare it to current market price, the 2026 growth guidance, and your risk tolerance before acting.

Does the SHC analyst rating guarantee stock gains?

No. An SHC analyst rating does not guarantee performance. Ratings reflect analyst views and can change. Always combine ratings with financials, guidance, and risk analysis.

Where can I read the analyst note and the earnings call that influenced the SHC analyst rating?

The price target change was reported by TheFly and the company’s Q4 2025 call transcript is on Seeking Alpha. See both sources for the analyst note and management commentary. [source](https://thefly.com/permalinks/entry.php/id4299702/9360286394/SHC-Sotera-Health-price-target-raised-by--at-Citi-heres

Analyst Ratings

Citigroup Maintains Buy on SHC (Sotera Health Company) Feb 24 2026, PT $23

ByDanny Kontos February 25, 2026

Citigroup maintained a Buy on Sotera Health Company (SHC) on February 24, 2026, and raised its price target to $23 from $21. This SHC analyst rating shows continued analyst confidence after Sotera’s Q4 2025 results and 2026 guidance. We review the Citi action, the new price target, and what investors should consider now. Meyka AI’s real-time coverage flagged the change and placed it in a broader market context.